Logo image of DCTH

DELCATH SYSTEMS INC (DCTH) Stock Fundamental Analysis

NASDAQ:DCTH - Nasdaq - US24661P8077 - Common Stock - Currency: USD

11.25  -0.07 (-0.62%)

After market: 11.62 +0.37 (+3.29%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to DCTH. DCTH was compared to 187 industry peers in the Health Care Equipment & Supplies industry. DCTH has a great financial health rating, but its profitability evaluates not so good. DCTH is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year DCTH has reported negative net income.
DCTH had a negative operating cash flow in the past year.
DCTH had negative earnings in each of the past 5 years.
DCTH had a negative operating cash flow in each of the past 5 years.
DCTH Yearly Net Income VS EBIT VS OCF VS FCFDCTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

With a Return On Assets value of -16.27%, DCTH perfoms like the industry average, outperforming 52.94% of the companies in the same industry.
With a decent Return On Equity value of -17.71%, DCTH is doing good in the industry, outperforming 63.10% of the companies in the same industry.
Industry RankSector Rank
ROA -16.27%
ROE -17.71%
ROIC N/A
ROA(3y)-120.78%
ROA(5y)-101.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DCTH Yearly ROA, ROE, ROICDCTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

1.3 Margins

DCTH has a better Gross Margin (84.90%) than 95.72% of its industry peers.
In the last couple of years the Gross Margin of DCTH has grown nicely.
DCTH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.01%
GM growth 5Y8.9%
DCTH Yearly Profit, Operating, Gross MarginsDCTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

8

2. Health

2.1 Basic Checks

DCTH does not have a ROIC to compare to the WACC, probably because it is not profitable.
DCTH has more shares outstanding than it did 1 year ago.
The number of shares outstanding for DCTH has been increased compared to 5 years ago.
DCTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DCTH Yearly Shares OutstandingDCTH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
DCTH Yearly Total Debt VS Total AssetsDCTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 26.31 indicates that DCTH is not in any danger for bankruptcy at the moment.
The Altman-Z score of DCTH (26.31) is better than 96.79% of its industry peers.
DCTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 26.31
ROIC/WACCN/A
WACC9.21%
DCTH Yearly LT Debt VS Equity VS FCFDCTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

DCTH has a Current Ratio of 15.95. This indicates that DCTH is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 15.95, DCTH belongs to the best of the industry, outperforming 96.26% of the companies in the same industry.
A Quick Ratio of 14.61 indicates that DCTH has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 14.61, DCTH belongs to the top of the industry, outperforming 96.79% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 15.95
Quick Ratio 14.61
DCTH Yearly Current Assets VS Current LiabilitesDCTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 81.75% over the past year.
DCTH shows a strong growth in Revenue. In the last year, the Revenue has grown by 1068.62%.
The Revenue has been growing by 88.10% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)81.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.67%
Revenue 1Y (TTM)1068.62%
Revenue growth 3Y118.63%
Revenue growth 5Y88.1%
Sales Q2Q%530.26%

3.2 Future

The Earnings Per Share is expected to grow by 31.72% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 44.98% on average over the next years. This is a very strong growth
EPS Next Y99.48%
EPS Next 2Y58.23%
EPS Next 3Y44.41%
EPS Next 5Y31.72%
Revenue Next Year166.43%
Revenue Next 2Y88.22%
Revenue Next 3Y65.81%
Revenue Next 5Y44.98%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
DCTH Yearly Revenue VS EstimatesDCTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
DCTH Yearly EPS VS EstimatesDCTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200M -400M -600M -800M -1B

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DCTH. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 22.79, which indicates a rather expensive current valuation of DCTH.
75.94% of the companies in the same industry are more expensive than DCTH, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.44, DCTH is valued a bit cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 22.79
DCTH Price Earnings VS Forward Price EarningsDCTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DCTH Per share dataDCTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

DCTH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
DCTH's earnings are expected to grow with 44.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.23%
EPS Next 3Y44.41%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DCTH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DELCATH SYSTEMS INC

NASDAQ:DCTH (7/18/2025, 8:00:01 PM)

After market: 11.62 +0.37 (+3.29%)

11.25

-0.07 (-0.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-11 2025-08-11/amc
Inst Owners43.17%
Inst Owner Change0.52%
Ins Owners2.61%
Ins Owner Change1.29%
Market Cap391.84M
Analysts85
Price Target24.48 (117.6%)
Short Float %4.8%
Short Ratio2.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-196.13%
Min EPS beat(2)-488.34%
Max EPS beat(2)96.08%
EPS beat(4)2
Avg EPS beat(4)-73.24%
Min EPS beat(4)-488.34%
Max EPS beat(4)129.41%
EPS beat(8)4
Avg EPS beat(8)-50.41%
EPS beat(12)5
Avg EPS beat(12)-39.18%
EPS beat(16)8
Avg EPS beat(16)-26.89%
Revenue beat(2)2
Avg Revenue beat(2)11.34%
Min Revenue beat(2)7.43%
Max Revenue beat(2)15.26%
Revenue beat(4)4
Avg Revenue beat(4)18.33%
Min Revenue beat(4)4.98%
Max Revenue beat(4)45.68%
Revenue beat(8)5
Avg Revenue beat(8)5.04%
Revenue beat(12)7
Avg Revenue beat(12)8.35%
Revenue beat(16)10
Avg Revenue beat(16)24.85%
PT rev (1m)0%
PT rev (3m)6.67%
EPS NQ rev (1m)75.02%
EPS NQ rev (3m)1297.01%
EPS NY rev (1m)-103.42%
EPS NY rev (3m)-107.35%
Revenue NQ rev (1m)3.07%
Revenue NQ rev (3m)18.7%
Revenue NY rev (1m)2.62%
Revenue NY rev (3m)14.56%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 22.79
P/S 7.28
P/FCF N/A
P/OCF N/A
P/B 4.88
P/tB 4.88
EV/EBITDA N/A
EPS(TTM)-0.5
EYN/A
EPS(NY)0.49
Fwd EY4.39%
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS1.55
BVpS2.3
TBVpS2.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.27%
ROE -17.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.9%
FCFM N/A
ROA(3y)-120.78%
ROA(5y)-101.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.01%
GM growth 5Y8.9%
F-Score6
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 463.51%
Cap/Sales 1.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.95
Quick Ratio 14.61
Altman-Z 26.31
F-Score6
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)208.01%
Cap/Depr(5y)235.23%
Cap/Sales(3y)4.01%
Cap/Sales(5y)12.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.67%
EPS Next Y99.48%
EPS Next 2Y58.23%
EPS Next 3Y44.41%
EPS Next 5Y31.72%
Revenue 1Y (TTM)1068.62%
Revenue growth 3Y118.63%
Revenue growth 5Y88.1%
Sales Q2Q%530.26%
Revenue Next Year166.43%
Revenue Next 2Y88.22%
Revenue Next 3Y65.81%
Revenue Next 5Y44.98%
EBIT growth 1Y96.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year258.8%
EBIT Next 3Y78.7%
EBIT Next 5YN/A
FCF growth 1Y66.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y69.8%
OCF growth 3YN/A
OCF growth 5YN/A